Press release
Press release
Maidenhead, UK: July 22, 2008, Sense Proteomic Ltd. today announced the appointment of The Sage Group as its business development consultant to assist in generating additional biomarker discovery partners. Building on its two external collaborations and its internal discovery programmes, Sense now hopes to partner with additional companies to fully exploit the power of its biomarker discovery platform.
Commenting on the appointment, Chris Lyddon, joint CEO, said, "We are pleased to be working with The Sage Group given their track record and their commercial expertise in the biomarker field. We believe discovery partners will shorten development timelines of both clinical diagnostics and biomarkers for clinical trials monitoring by applying our unique autoantibody biomarker technology."
Dr. Bill Mason, Executive Director of The Sage Healthcare Group added, "Sense's novel approach will allow diagnostic and pharmaceutical companies to develop more predictive markers in the important areas of cancer and autoimmune diseases. We are pleased to be working with them to help them achieve their goals."
Sense Proteomic Limited is a biomarker discovery company utilising its proprietary protein array technology to discover and commercialise autoantibody biomarkers for cancer and autoimmune diseases.
The Sage Group is a leader in the provision of strategic and transactional advice to healthcare and life science companies in the diagnostics, medical device, pharmaceutical, biotechnology, life science and analytical instrument fields.
|
Chris Lyddon - Joint CEO |
Dr. Bill Mason - Executive Director |
Wayne Pambianchi - Executive Director
|